{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"groups":[{"description":"Patients receive cyclophosphamide IV and rituximab IV on day 1, oral prednisone on days 2-6, and bortezomib IV (at the MTD determined in phase I) on days 2, 5, 9, and 12. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.\n\nrituximab: Given IV\n\nbortezomib: Given IV\n\ncyclophosphamide: Given IV\n\nprednisone: Given orally","id":"OG000","title":"Arm I"},{"description":"Patients receive cyclophosphamide IV and rituximab IV on day 1, oral prednisone on days 2-6, and bortezomib IV (at the MTD determined in phase I) on days 2 and 8. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.\n\nrituximab: Given IV\n\nbortezomib: Given IV\n\ncyclophosphamide: Given IV\n\nprednisone: Given orally","id":"OG001","title":"Arm II"}],"populationDescription":"Data were not collected","reportingStatus":"POSTED","timeFrame":"2 years","title":"Progression-free Survival","type":"SECONDARY"}